New heart implant aims to prevent strokes without blood thinners

NCT ID NCT06465459

Recruiting now Disease control Sponsor: French Cardiology Society Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a device called LambrE that is implanted in the heart to close off a small pouch (the left atrial appendage) where blood clots often form in people with atrial fibrillation. The goal is to prevent strokes in patients who cannot take blood thinners due to bleeding risks. The study will follow 220 participants to see how well the device works and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LAMBRE device (a small implant placed in the heart to close off the left atrial appendage)
What this could lead to: If successful, this device could offer a safe alternative to blood thinners for preventing strokes in people with atrial fibrillation who cannot take anticoagulant medication.
What could go wrong: This is a post-marketing study, not a randomized trial, so results may not prove superiority over other treatments. There is a risk of device migration or other complications, and the study is relatively small (220 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Hôpital Cardiologique de Haut Lévêque
RECRUITING

Pessac, 33600, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.